Literature DB >> 20807145

Effects of topical administration of latanoprost, timolol, or a combination of latanoprost and timolol on intraocular pressure, pupil size, and heart rate in clinically normal dogs.

Lynsey N Smith1, Paul E Miller, Lisa M Felchle.   

Abstract

OBJECTIVE: To determine effects after topical administration of latanoprost, timolol, or a commercially available latanoprosttimolol combination twice daily on intraocular pressure (IOP), pupil size (PS), and heart rate (HR) in clinically normal dogs. ANIMALS: 17 clinically normal dogs. PROCEDURES: A randomized controlled clinical trial was performed with a treatment (n=9) and saline (0.9% NaCl) solution group (8). Each dog in the treatment group received 3 treatments (latanoprost, timolol, and the latanoprost-timolol combination), with a 14-day washout period between treatments. Baseline values were established on day 1 of each treatment period. On days 2 through 5, drugs were administered topically every 12 hours to 1 eye of each dog in the treatment group. In both groups, IOP PS, and HR were measured at 0, 2, 4, 6, 8, and 9 hours on days 2 and 5.
RESULTS: Eyes treated with latanoprost or the latanoprost-timolol combination had a significant decrease in IOP and a significantly smaller PS, compared with results for dogs receiving only timolol or dogs in the saline solution group. Timolol and the latanoprost-timolol combination both significantly lowered HR, compared with HR following administration of latanoprost and the saline solution. CONCLUSIONS AND CLINICAL RELEVANCE: Topical administration of latanoprost alone was as effective at lowering IOP as was administration of the latanoprost-timolol combination when both were given every 12 hours to clinically normal dogs. Timolol, either alone or in combination with latanoprost, appeared to have little or no effect on IOP in clinically normal dogs but was associated with a reduction in HR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807145     DOI: 10.2460/ajvr.71.9.1055

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  7 in total

1.  Safety and efficacy of topically administered netarsudil (Rhopressa™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).

Authors:  Kelly A Leary; Kuan-Ting Lin; Juan P Steibel; Christine D Harman; András M Komáromy
Journal:  Vet Ophthalmol       Date:  2019-12-24       Impact factor: 1.644

2.  Effects of 0.2% brimonidine and 0.2% brimonidine-0.5% timolol on intraocular pressure and pupil size in normal equine eyes.

Authors:  M Von Zup; M Lassaline; P H Kass; P E Miller; S M Thomasy
Journal:  Equine Vet J       Date:  2017-06-05       Impact factor: 2.888

3.  Safety and efficacy of topically administered netarsudil-latanoprost fixed dose combination (FDC; Rocklatan™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).

Authors:  Kelly A Leary; Juan P Steibel; Christine D Harman; Amanda L Anderson; András M Komáromy
Journal:  Vet Ophthalmol       Date:  2021-06-04       Impact factor: 1.644

Review 4.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

5.  Effects of topical administration of tafluprost and combination of tafluprost and timolol or tafluprost and betaxolol on Schirmer tear test, intraocular pressure, and pupil size in clinically healthy dogs.

Authors:  Armin Shokoohimand; Farnoosh Arfaee; Ahmad Asghari; Ehsan Khaksar
Journal:  Int Ophthalmol       Date:  2020-06-05       Impact factor: 2.031

6.  Pharmacological Profile and Ocular Hypotensive Effects of Cromakalim Prodrug 1, a Novel ATP-Sensitive Potassium Channel Opener, in Normotensive Dogs and Nonhuman Primates.

Authors:  Uttio Roy Chowdhury; Rachel A Kudgus; Bradley H Holman; Tommy A Rinkoski; Cheryl R Hann; Cindy K Bahler; Eric McCloud; Susan E Appt; Joel M Reid; Peter I Dosa; Michael P Fautsch
Journal:  J Ocul Pharmacol Ther       Date:  2021-03-30       Impact factor: 2.850

Review 7.  Remodeling of the Lamina Cribrosa: Mechanisms and Potential Therapeutic Approaches for Glaucoma.

Authors:  Ryan G Strickland; Mary Anne Garner; Alecia K Gross; Christopher A Girkin
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.